Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KHK2455 + Mogamulizumab in Advanced Solid Tumors
NCT02867007Phase 1Completed
- Sponsor
- Kyowa Kirin
- Start
- Aug 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HTX-201 in solid tumor, sponsored by Kyowa Kirin. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 2 years. Started Aug 2016; status: completed.
02
Drugs
HTX-201
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02867007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02867007.